Cargando…
The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes
Podocytes have a unique structure that supports glomerular filtration function, and many glomerular diseases result in loss of this structure, leading to podocyte dysfunction and ESRD (end stage renal disease). These structural and functional changes involve a complex set of molecular and cellular m...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981397/ https://www.ncbi.nlm.nih.gov/pubmed/31906131 http://dx.doi.org/10.3390/ijms21010274 |
_version_ | 1783491070456233984 |
---|---|
author | Solanki, Ashish K. Srivastava, Pankaj Rahman, Bushra Lipschutz, Joshua H. Nihalani, Deepak Arif, Ehtesham |
author_facet | Solanki, Ashish K. Srivastava, Pankaj Rahman, Bushra Lipschutz, Joshua H. Nihalani, Deepak Arif, Ehtesham |
author_sort | Solanki, Ashish K. |
collection | PubMed |
description | Podocytes have a unique structure that supports glomerular filtration function, and many glomerular diseases result in loss of this structure, leading to podocyte dysfunction and ESRD (end stage renal disease). These structural and functional changes involve a complex set of molecular and cellular mechanisms that remain poorly understood. To understand the molecular signature of podocyte injury, we performed transcriptome analysis of cultured human podocytes injured either with PAN (puromycin aminonucleoside) or doxorubicin/adriamycin (ADR). The pathway analysis through DE (differential expression) and gene-enrichment analysis of the injured podocytes showed Tumor protein p53 (P53) as one of the major signaling pathways that was significantly upregulated upon podocyte injury. Accordingly, P53 expression was also up-regulated in the glomeruli of nephrotoxic serum (NTS) and ADR-injured mice. To further confirm these observations, cultured podocytes were treated with the P53 inhibitor pifithrin-α, which showed significant protection from ADR-induced actin cytoskeleton damage. In conclusion, signaling pathways that are involved in podocyte pathogenesis and can be therapeutically targeted were identified by high-throughput transcriptomic analysis of injured podocytes. |
format | Online Article Text |
id | pubmed-6981397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69813972020-02-07 The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes Solanki, Ashish K. Srivastava, Pankaj Rahman, Bushra Lipschutz, Joshua H. Nihalani, Deepak Arif, Ehtesham Int J Mol Sci Article Podocytes have a unique structure that supports glomerular filtration function, and many glomerular diseases result in loss of this structure, leading to podocyte dysfunction and ESRD (end stage renal disease). These structural and functional changes involve a complex set of molecular and cellular mechanisms that remain poorly understood. To understand the molecular signature of podocyte injury, we performed transcriptome analysis of cultured human podocytes injured either with PAN (puromycin aminonucleoside) or doxorubicin/adriamycin (ADR). The pathway analysis through DE (differential expression) and gene-enrichment analysis of the injured podocytes showed Tumor protein p53 (P53) as one of the major signaling pathways that was significantly upregulated upon podocyte injury. Accordingly, P53 expression was also up-regulated in the glomeruli of nephrotoxic serum (NTS) and ADR-injured mice. To further confirm these observations, cultured podocytes were treated with the P53 inhibitor pifithrin-α, which showed significant protection from ADR-induced actin cytoskeleton damage. In conclusion, signaling pathways that are involved in podocyte pathogenesis and can be therapeutically targeted were identified by high-throughput transcriptomic analysis of injured podocytes. MDPI 2019-12-31 /pmc/articles/PMC6981397/ /pubmed/31906131 http://dx.doi.org/10.3390/ijms21010274 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Solanki, Ashish K. Srivastava, Pankaj Rahman, Bushra Lipschutz, Joshua H. Nihalani, Deepak Arif, Ehtesham The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes |
title | The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes |
title_full | The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes |
title_fullStr | The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes |
title_full_unstemmed | The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes |
title_short | The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes |
title_sort | use of high-throughput transcriptomics to identify pathways with therapeutic significance in podocytes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981397/ https://www.ncbi.nlm.nih.gov/pubmed/31906131 http://dx.doi.org/10.3390/ijms21010274 |
work_keys_str_mv | AT solankiashishk theuseofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT srivastavapankaj theuseofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT rahmanbushra theuseofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT lipschutzjoshuah theuseofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT nihalanideepak theuseofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT arifehtesham theuseofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT solankiashishk useofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT srivastavapankaj useofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT rahmanbushra useofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT lipschutzjoshuah useofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT nihalanideepak useofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes AT arifehtesham useofhighthroughputtranscriptomicstoidentifypathwayswiththerapeuticsignificanceinpodocytes |